Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Semaglutide vs Tirzepatide: A Physician's Head-to-Head Comparison (2026) If you're considering a GLP-1 medication for weight loss, you've probably encountered two names more than any others: semaglutide and tirzepatide
Use the linked related pages or supporting resources on the site for a broader view, then come back to this page once you have the context you need.
W.AbbottC
These findings are systematically collated in Table 1, which provides an overview of microbial taxa altered by GLP-1RAs (Table 1)
Semaglutide (Ozempic/Wegovy) Timeline Phase 3 trials began: 2015 (SUSTAIN program for diabetes) FDA approval (Ozempic for diabetes): December 2017 Commercial availability: Early 2018 Wegovy (obesity indication) Phase 3: 2018-2020 (STEP program) Wegovy FDA approval: June 2021 Wegovy commercial launch: September 2021, immediately went into shortage due to overwhelming demand Stable widespread availability: Mid-2023 (after Novo Nordisk scaled up manufacturing) Total time from Phase 3 start to stable availability: About 8 years for diabetes indication, 5 years for obesity indication (but with significant supply constraints)
US$ 29.17
US$ 26.60
US$ 20.26
US$ 21.16
US$ 26.61
US$ 26.48
US$ 27.61
US$ 28.79
US$ 21.53
US$ 24.28
US$ 22.65
US$ 23.49
US$ 21.00
US$ 26.97
